Sonja Zweegman, MD, PhD, Head of the Department of Hematology and Vice Chair of the Cancer Center Amsterdam at Amsterdam UMC, has been awarded the 2025 Brian G.M. Durie Outstanding Achievement Award. The award was presented on June 10 during the 16th Annual International Myeloma Working Group (IMWG) Summit in Milan, Italy.
Titel
Inhoud

Each year, the International Myeloma Foundation (IMF) presents this distinguished award to a researcher who has made outstanding contributions to the field of multiple myeloma. Prof. Zweegman is recognized for her tireless commitment to improving treatment strategies, especially for vulnerable and elderly myeloma patients.

As Chair of the Dutch HOVON Myeloma Working Group and co-leader of the Amsterdam UMC Myeloma Translational Research Group, Prof. Zweegman has led pioneering work in personalized medicine and immunotherapy—including the development of novel CAR T-cell treatments. Her research bridges laboratory science and clinical care, with a strong focus on enhancing quality of life, minimizing treatment toxicity, and centering care around patient values.

“It’s a real honor to receive this award, especially as it carries the name that marked my very first steps into the world of myeloma—Brian G.M. Durie,” said Prof. Zweegman. “This award belongs to the entire team in Amsterdam, to the international myeloma community, and above all, to the patients I work with. Together, we are on a shared journey to achieve longer and better lives for people living with myeloma.”

The full award announcement and Prof. Zweegman’s remarks can be read in the official press release by the International Myeloma Foundation.

The Brian G.M. Durie Outstanding Achievement Award recognizes excellent achievements in multiple myeloma research. Professor of Medicine, Hematologist/Oncologist, and Honoree MD at the University of Brussels, Dr. Brian G.M. Durie is the Chief Scientific Officer of the IMF. Dr. Durie is also the Chairman of the IMWG and leads the IMF’s Black Swan Research Initiative®(BSRI).